A competitive drug market strongly encourages companies to best their rivals by developing the next generation of life-saving therapies.

U.S. stocks rallied over the trading week, shortened by the Thanksgiving holiday and a reduced trading session on Friday. The S&P 500 was up around 4% during the week, while the Dow rose a similar ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses ...

Share on PinterestNovo Nordisk has announced the cessation of the Evoke trials, looking at whether GLP-1 drugs could help ...

President implored Republicans to make a better case for how much prices are easing in America ahead of next year's mid-term ...

The share price of Danish pharmaceutical giant Novo Nordisk ( NVO +1.25%) hit a four-year low Monday, falling below $44 a ...

If you're a growth-oriented investor looking for a no-brainer stock to buy with a rock-solid balance sheet and a track record ...

I also own Eli Lilly, too, so I can handle that pain. Lilly may have the greatest drug franchise of all time with this GLP-1 ...

The next-generation “GLP-1 plus” drugs will be tailored to the health needs of individual patients.

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment ...

Novo Nordisk A/S (NVO), though cheap at 13x forward earnings, is in my view a value trap, as growth is slowing and GLP-1 ...

Eli Lilly announced trial results for its weight-loss medication, orforglipron, in August. Orforglipron is a once-daily oral ...